Zusammenfassung
Die Leberzirrhose ist eine chronische Leberkrankheit, die langsam entsteht und allmählich durch ständig zugrundegehendes Lebergewebe und dieses ersetzendes Bindegewebe zu irreversiblen Veränderungen führt. Auslöser des allmählichen Leberumbaus sind chronische Leberkrankheiten oder chronisch auf die Leber einwirkende Noxen. Betroffen ist immer das gesamte Organ. Die Krankheit kann asymptomatisch verlaufen oder mit wenigen uncharakteristischen oder auch starken Beschwerden einhergehen, die dann häufig auf lebensbedrohliche Komplikationen hinweisen. Die wichtigsten Komplikationen der Leberzirrhose sind der Aszites, die Ösophagusvarizenblutung und die hepatische Enzephalopathie.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Gerok W (1984) Leberzirrhose. In: Demling L (Hrsg) Klinische Gastroenterologie. Thieme, Stuttgart, New York, Bd II, S 115–151
Gerok W (1981) Therapie der Protein– und Aminosäurenstoffwechselstörungen bei Leberkrankheiten. Leber-Magen-Darm 11: 63–72
Köllinger M, Kullmann F, Holstege A, Schölmerich J (1996) Prophylaxe und Therapie von Komplikationen der Leberzirrhose: Aszites, Enzephalopathie und Malnutrition. Med Klin 91: 89–102
Melato M, Mucli E (1989) Something new in liver cirrhosis epidemiology. Lancet 2: 395–396
Müller MJ, Lantz HU, Selberg O, Canzler H, Schmidt FW (1991) Ernährung bei chronischen Leberkrankheiten. Dtsch Med Wochenschr 116: 909–916
Epstein FH, Post RS, McDowell M (1953) The effect of an arteriovenous fistula on renal he-modynamics and electrolyte excretion. J Clin Invest 32: 233–241
Epstein M (1991) Renal disorders in liver disease. In: Suki WN, Massry SG (Hrsg.) Therapy of renal diseases and related disorders, 2nd edn. Kluwer, Dordrecht, S 477–493
Epstein M (1989) Treatment of refractory ascites. N Engl J Med 321: 220–228
Nicholls KM, Shapiro MD, Groves BS, Schrier RW (1986) Factors determining renal response to water immersion in non-excretor cirrhotic patients. Kidney Int 30: 417–421
Philipp T, Köhler H (1994) Gastrointestinale Systeme (einschließlich Leber). In: Brass H, Philipp T, Schulz W (Hrsg) Manuale Nephrologicum Dustri, Deisenhofen, VII 4/7, S 1–11
Schrier RW, Caramelo C (1987) Hemodynamics and hormonal alterations in hepatic cirrhosis. In: Epstein M (Hrsg) The kidney in liver disease. Williams & Wilkins, New York
Schrier RW (1988) Pathogenesis of sodium and water retention in high-output and low-out- put cardiac failure, nephrotic syndrome, cirrhosis and pregnancy. N Engl J Med 319: 1127–1134
Epstein M (1982) Peritoneovenous shunt in the management of ascites and the hepatorenal
syndrome. Gastroenterology 82:790–794
Epstein M (1989) Treatment of refractory ascites. N Engl J Med 321: 1675–1677
Gerbes AL, Paumgartner G (1994) Diagnostik des Aszites. Dtsch Med Wochenschr 119: 1507–1511
Gerbes AL, Paumgartner G (1994) Therapie des Aszites bei Lebererkrankungen. Dtsch Med Wochenschr 119: 1549–1554
Ginés P, Titó L, Arroyo Vet al. (1988) Randomized comparative study of therapeutic paracentesis with and without albumin in cirrhosis. Gastroenterology 94: 1493–1502
Pinzani M, Daskalopoulos G, Laffi G, Gentilini P, Zipser RD (1987) Altered furosemide pharmacokinetics in chronic alcoholic liver disease with ascites contributes to diuretic resistance. Gastroenterology 92: 294–298
Schölmerich J, Zimmermann U, Röttgen E et al. (1988) Proteases and antiproteases related to the coagulation system in plasma and ascites. Prediction of coagulation disorders in ascites retransfusion. J Hepatol 6: 359–363
Schölmerich J (1991) Aszites. Pathophysiologic - Diagnostik - Therapie. Springer, Berlin Heidelberg New York Tokyo
Arroyo V, Navasa M, Rimola A (1994) Spontaneous bacterial peritonitis in liver cirrhosis:
Treatment and prophylaxis. Infection 22 (Suppl. 3):167–175
Cabre E, Gonzalez-Huix F, Abad-Lacruz A et al. (1990) Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. Gastroenterology 98: 715–720
Gilbert JA, Kamath PS (1995) Spontaneous bacterial peritonitis: An update. Mayo Clin Proc 70: 365–370
Press AG, Meyer zum Büschenfelde KH, Ramadori G (1992) Die spontane bakterielle Perito¬nitis. Z Gastroenterol 30: 543–552
Rimola A, Navasa M, Arroyo V (1995) Experience with cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis. Diagn Microbiol Infect Dis 22: 141–145
Rolando N, Harvey F, Brahm J et al. (1990) Prospective study of bacterial infection in acute liver failure: An analysis of fifty cases. Hepatology 11: 49–53
Runyon BA, van Epps DE (1986) Diuresis of cirrhotic ascites increases its opsonic activity and may help prevent spontaneous bacterial peritonitis. Hepatology 6: 396–399
Schölmerich J, Gerbes AL, Andus T, Leser H-G (1995) Spontane bakterielle Peritonitis bei Leberzirrhose mit Aszites. Dtsch Med Wochenschr 120: 454–461
Soriano G, Guarner C, Teixido M et al. (1991) Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 100: 477–481
Tito L, Rimola A, Gines P et al. (1988) Recurrence of spontaneous bacterial peritonitis in cirrhosis: Frequency and predictive factors. Hepatology 8: 27–31
Angelico M, Carli L, Piat C et al. (1993) Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Gastroenterology 104: 1460–1465
Besson I, Ingrand P, Person B et al. (1995) Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 333: 555–560
Brocchi E, Caletti G, Brambilla G et al. (1988) Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 319: 983–989
Conn HO, Rambsby GR, Storer EH et al. (1975) Intraarterial vasopressin in the treatment of upper gastrointestinal hemorrhage: a prospective controlled clinical trial. Gastroenterology 68: 211–221
D’Amico G, Pagliaro L, Bosch J (1995) The treatment of portal hypertension: A meta-analytic review. Hepatology 22: 332–354
Feretis C, Dimopoulos C, Benakis P, Kalliakmanis B, Apostolidis N (1995) N-butyl-2-cya- noacrylate (Histoacryl) plus sclerotherapy versus sclerotherapy alone in the treatment of bleeding esophageal varices: a randomized prospective study. Endoscopy 27: 355–357
Ganguly S, Sarin SK, Bhatia V, Lahoti D (1995) The prevalence and spectrum of colonic lesions in patients with cirrhotic and noncirrhotic portal hypertension. Hepatology 21: 1226–1231
Grace ND (1992) Prevention of initial variceal hemorrhage. Gastroenterol Clin North Am 21: 149–161
Hashizume M, Kitano S, Koyanagi N (1992) Endoscopic injection sclerotherapy for 1000 patients with esophageal varices: A nine-year prospective study. Hepatology 15:69– 75
Jutabha R, Jensen DM, See J, Machicado G, Hirabayashi K (1995) Randomized, controlled study of various agents for endoscopic injection sclerotherapy of bleeding canine gastric varices. Gastrointest Endosc 41: 206–211
Kitano S, Terblanche J, Kahn D, Bornman PC (1986) Venous anatomy of the lower oesophagus in portal hypertension: Practical implication. Br J Surg 73: 525–531
Kleber G, Sauerbruch T, Ansari H, Paumgartner G (1991) Prediction of variceal hemorrhage in cirrhosis: A prospective follow-up study. Gastroenterology 100: 1332–1337
Lebrec D, Poynard T, Hillon P, Benhamou J (1981) Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. N Engl J Med 305: 1371–1374
Orlof MJ, Orloff MS, Orlff SL, Haynes KS (1995) Treatment of bleeding from portal hypertensive gastropathy by portocaval shunt. Hepatology 21: 1011–1017
Rigo GP, Merighi A, Chahin NJ et al. (1992) A prospective study of the ability of three endoscopic classifications to predict hemorrhage from esophageal varices. Gastrointest Endosc 38: 425–429
Soehendra N, Nam VC, Grimm H, Kempeneers I (1986) Endoscopic obliteration of large esophageal varcies with bycrylate. Endoscopy 18: 25–26
Stiegmann GV, Goff JS, Michaletz-Onody PA (1992) Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med 326:1527– 1532
Thakeb F, Salama Z, Raouf TA, Kader SA, Hamid HA (1995) The value of combines use of N-butyl-2-cyanoacrylate and ethanolamine oleate in the management of bleeding oeso- phagogastric varices. Endoscopy 27: 358–364
The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices (1988): Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A protective multicenter study. N Engl J Med 319: 983–989
Vianna A, Hayes PC, Moscoso G, Driver M, Portmann B, Westaby D, Williams R (1987) Normal venous circulation of the gastroesophageal junction: A route to understanding varices. Gastroenterology 93: 876–889
Bizollon T (1991) Fibrinolytic therapy for portal vein thrombosis. Lancet 337: 1416
Carmassi F, Morale M, De Negri F, Carrai M (1995) Modulation of hemostatic balance with antithrombin III replacement therapy in a case of liver cirrhosis associated with recurrent venous thrombosis. J Mol Med 73: 89–93
DeCaterina MI, Tarantino G, Farina C (1993) Haemostasis unbalance in Pugh-scored liver cirrhosis; Characteristic changes of plasma levels of protein C versus Protein S. Haemostasis 23: 229
Mammen EF (1994) Coagulopathies of liver disease. Clin Lab Med 14: 769–780
Mann O, Haag K, Hauenstein KH, Rössle M, Pausch J (1995) Septische Pfortaderthrombose. Dtsch Med Wochenschr 120: 1201–1206
Mannucci PM, Vicente V, Vianello L (1986) Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 67: 1148
Scharrer I, Encke A, Hottenrott C (1988) Clinical cure of haemophilia A by liver transplantation. Lancet 1: 800–801
Scharrer I (1995) The need for highly purified products to treat hemophilia B. Acta Haematologica 94 (Suppl. l): 2–7
Violi F, Ferro D, Basili S, Artini M, Valesini G, Levrero M, Cordova C (1995) Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationships to venous thrombosis. J Invest Med 43: 550–554
Violi F, Ferro D, Basili S, Cimminiello C, Saliola M,Vezza E,Cordova C, and the CALC Group(1995) Prognostic value of clothing and fibrinolytic systems in a follow-up of 165 liver cirrhotic patients. Hepatology 22: 96–100
Basile AS, Hughes RD, Harrison PM, Murata Y, Pannell L, Jones EA et al. (1991) Elevated brain concentrations of 1,4-benzodiazepine in fulminant hepatic failure. N Engl J Med 325: 473–478
Butterworth RF (1995) Hepatic encephalopathy. Neurologist 1: 95–104
Candranel JF, El Younsi M, Pidoux B, Zylberberg P, Benhamou Y, Valla D et al. (1995) Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study. Europ J Gastroenterol Hepatol 7: 325–329
Charlton MR (1996) Branched chains revisited. Gastroenterology 111: 252–255
Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seef L, Levy LL (1977) Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: a double blind controlled trial. Gastroenterology 72: 573–583
Ferenci P, Püspök A, Steindl P (1992) Current concepts in the pathophysiology of hepatic
encephalopathy. Eur J Clin Invest 22:573–581
Gyr K, Meier R, Häussler J, Bouletreau P, Fleig WE, Gatta A et al (1996) Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomized, placebo controlled multicentre study. Gut 39: 319–324.
Häussinger D, Maier KP (Hrsg) (1996) Hepatische Enzephalopathie. Thieme, Stuttgart
Häussinger D, Laubenberger J, vom Dahl S, Ernst T, Bayer S, Langer M et al. (1994) Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology 107: 1475–1480
Holstege A, Lock G, Köllinger M, Schölmerich J (1996) Conservative treatment of acute hepatic failure. Z Gastroenterologie 34: 192–201
Kircheis G, Quack G, Erbler H (1994) L-ornithine-L-aspartate (OA) in the treatment of hyperammoniemia and hepatic encephalopathy - experimental aspects and clinical trials. In: Conn HO, Bircher J (Hrsg) Hepatic encephalopathy: Syndromes and therapies. Medi- Ed Press, Bloomington, S 373–383
Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Görtelmeyer R et al (1997) Hepatology 25: 1351–1360
Koch H, Schauder P, Schäfer G, Dahme B, Ebel W, Vahldiek B et al. (1990) Untersuchungen zur Diagnose und Prävalenz der latenten hepatischen Encephalopathie. Z Gastroenterolo¬gie 28: 610–615
Köllinger M, Kullmann F, Holstege A, Schölmerich J (1996) Prophylaxe und Therapie von Komplikationen der Leberzirrhose: Aszites, Enzephalopathie und Malnutrition. Med Klin 91: 89–102
Lee WM (1993) Acute liver failure. N Engl J Med 329: 1862–1872
Lee WM (1995) Drug-induced hepatotoxicity. N Engl J Med 333: 1118–1127
Naylor CD, O’Rorke K, Detsky AS, Baker JP (1989) Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. Gastroenterology 97: 1033–1042
Pomier-Layrargues G, Giguere JF, Lavoie J, Perney P, Gagnon S, Damour M, Wells J, Butterworth RF (1994) Flumazenil in cirrhotic patients in hepatic coma: a randomized double- blind placebo-controlled crossover trial. Hepatology 19: 32–37
Record CO (1991) Neurochemistry of hepatic encephalopathy. Gut 32: 1261–1263
Riggio O, Balducci G, Ariosta F, Merli M, Temitera S, Ziparo V, Capocaccia L (1990) Lactitol in the treatment of chronic hepatic encephalopathy: a randomized cross-over comparison with lactulose. Hepatogastroenterol 37: 524–527
Riggio O, Ariosto F, Merli M, Caschera M, Zullo A, Balducci G, Ziparo V, Pedrett G, Fiacca- dori F, Bottari E, Capocaccia L (1991) Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind cross-over trial. Dig Dis Sci 36: 1204–1208
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Leuschner, U. et al. (1997). Leberzirrhose und Komplikationen. In: Caspary, W.F., Leuschner, U., Zeuzem, S. (eds) Therapie von Leber- und Gallekrankheiten. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-97978-1_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-97978-1_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-97979-8
Online ISBN: 978-3-642-97978-1
eBook Packages: Springer Book Archive